575 related articles for article (PubMed ID: 26345307)
1. New developments in atherosclerosis: clinical potential of PCSK9 inhibition.
Giunzioni I; Tavori H
Vasc Health Risk Manag; 2015; 11():493-501. PubMed ID: 26345307
[TBL] [Abstract][Full Text] [Related]
2. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
3. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
4. PCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9.
Tavori H; Giunzioni I; Fazio S
Curr Opin Endocrinol Diabetes Obes; 2015 Apr; 22(2):126-32. PubMed ID: 25692926
[TBL] [Abstract][Full Text] [Related]
5. PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab.
Blom DJ; Dent R; Castro RC; Toth PP
Vasc Health Risk Manag; 2016; 12():185-97. PubMed ID: 27274264
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of PCSK9: a novel approach for the treatment of dyslipidemia.
Stawowy P; Just IA; Kaschina E
Coron Artery Dis; 2014 Jun; 25(4):353-9. PubMed ID: 24667128
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin/kexin type 9: the available clinical evidence.
Cicero AF; Tartagni E; Ertek S
Expert Opin Biol Ther; 2014 Jun; 14(6):863-8. PubMed ID: 24661068
[TBL] [Abstract][Full Text] [Related]
8. On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects.
Tavori H; Rashid S; Fazio S
Atherosclerosis; 2015 Feb; 238(2):264-70. PubMed ID: 25544176
[TBL] [Abstract][Full Text] [Related]
9. Alirocumab as add-on therapy to statins: current evidence and clinical potential.
Auer J; Berent R
Ther Adv Cardiovasc Dis; 2018 Jul; 12(7):191-202. PubMed ID: 29792380
[TBL] [Abstract][Full Text] [Related]
10. Atherosclerosis stabilization with PCSK-9 inhibition: An evolving concept for cardiovascular prevention.
Robinson JG; Heistad DD; Fox KA
Atherosclerosis; 2015 Dec; 243(2):593-7. PubMed ID: 26545013
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction.
Henry CA; Lyon RA; Ling H
Vasc Health Risk Manag; 2016; 12():163-9. PubMed ID: 27143910
[TBL] [Abstract][Full Text] [Related]
12. PCSK9 inhibition in patients with hypercholesterolemia.
Desai NR; Sabatine MS
Trends Cardiovasc Med; 2015 Oct; 25(7):567-74. PubMed ID: 25771732
[TBL] [Abstract][Full Text] [Related]
13. PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels.
Marais AD; Kim JB; Wasserman SM; Lambert G
Pharmacol Ther; 2015 Jan; 145():58-66. PubMed ID: 25046268
[TBL] [Abstract][Full Text] [Related]
14. PCSK9 Inhibitors: Are We on the Verge of a Breakthrough?
Yang E
Clin Pharmacol Ther; 2015 Dec; 98(6):590-601. PubMed ID: 26369501
[TBL] [Abstract][Full Text] [Related]
15. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
Joseph L; Robinson JG
Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
[TBL] [Abstract][Full Text] [Related]
16. Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction.
Tavori H; Melone M; Rashid S
Expert Rev Cardiovasc Ther; 2014 Oct; 12(10):1137-44. PubMed ID: 25244623
[TBL] [Abstract][Full Text] [Related]
17. Low Density Lipoprotein (LDL) Cholesterol as a Causal Role for Atherosclerotic Disease: Potential Role of PCSK9 Inhibitors.
Del Pinto R; Grassi D; Properzi G; Desideri G; Ferri C
High Blood Press Cardiovasc Prev; 2019 Jun; 26(3):199-207. PubMed ID: 31236902
[TBL] [Abstract][Full Text] [Related]
18. PCSK9 inhibitors: monoclonal antibodies for the treatment of hypercholesterolemia.
Paton DM
Drugs Today (Barc); 2016 Mar; 52(3):183-92. PubMed ID: 27186592
[TBL] [Abstract][Full Text] [Related]
19. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of proprotein convertase subtilisin/kexin type 9: focus on potential clinical and therapeutic implications for low-density lipoprotein cholesterol lowering.
Lose JM; Dorsch MP; Bleske BE
Pharmacotherapy; 2013 Apr; 33(4):447-60. PubMed ID: 23553812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
